Many established medical therapies to treat myasthenia gravis remain in use, and newer options are available for patients who ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the ...

UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB's ...

Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies. The myasthenia gravis (MG) market ...

A new approach induces the patient’s body to produce its own CAR-T cells, relying on the same messenger RNA (mRNA) technology ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Does anyone really listen to prescription drug commercials on television? Virtually all these ads come with a long list of scary side effects. It’s hard to believe that people would badger their ...